Healthcare Industry News: Novo Nordisk
News Release - April 25, 2006
ZymoGenetics Names Michael Dwyer Senior Vice President of Marketing and SalesrhThrombin Phase 3 Clinical Trial Progressing as Planned
SEATTLE, April 25 (HSMN NewsFeed) -- ZymoGenetics, Inc. (Nasdaq: ZGEN ) announced today that Michael J. Dwyer will join the company in May as Senior Vice President of Marketing and Sales and as a member of the Executive Management Committee. Mr. Dwyer has nearly thirty years experience in biologic and pharmaceutical marketing and sales, with expertise in marketing execution, sales management and sales operations. He will be responsible for continuing to build ZymoGenetics' sales, marketing and operations/logistics team in preparation for anticipated launch of recombinant human thrombin (rhThrombin) in late 2007.
"Mike's expertise in marketing and sales will be a tremendous asset to ZymoGenetics as we prepare for the anticipated commercialization of rhThrombin. His experience in building successful commercial operations from the ground up and leading sales teams selling directly to hospitals will be critical to a successful market launch," said Bruce L.A. Carter, Ph.D., President and Chief Executive Officer of ZymoGenetics. "I'm also pleased to report that our rhThrombin Phase 3 clinical trial and other development programs are moving ahead as planned."
During his career, Mr. Dwyer has held positions in marketing and sales at Bayer/Miles Inc. where he assisted in developing the introductory strategy and product launch for Kogenate® (recombinant Factor VIII). As Manager of Business Development and Marketing for Home Care and New Products, Mr. Dwyer helped create marketing plans for biological products in clinical trials and instituted uniform pricing and contractual guidelines. Mr. Dwyer also served as Vice President of Marketing and Materials Management for Caremark Therapeutic Services, a biopharmaceutical provider of home therapies and services for individuals with chronic disorders such as rheumatoid arthritis or hepatitis C.
More recently, Mr. Dwyer developed and executed strategic plans to build new therapeutic markets and drive market shares for two product launches. He devised launch strategies, designed operations and recruited field sales forces for the U.S. launch of NovoSeven® and Norditropin®. Most recently, Mr. Dwyer was responsible for planning and implementing selling strategies for an 850 person health care sales team in eight regions as Vice President, Diabetes Sales for Novo Nordisk. In this position, Mr. Dwyer led highly motivated sales teams and oversaw expansion strategies, market penetration and key opinion leader development. He improved operational efficiency by establishing a sales force automation system. Mr. Dwyer holds an M.B.A. from Pepperdine University and a B.S. from University of Dayton.
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.